Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Acute Effects of Caffeine on Repeated Sprint Performance and Energy Distribution

18 de mayo de 2026 actualizado por: Abdulkadir Birol, Trabzon University

Acute Effect of Caffeinated and Decaffeinated Coffee Consumption on Repeated Sprint Performance and Energy Contribution Distribution

The goal of this study is to learn if low-dose caffeinated coffee improves repeated sprint performance and affects energy system contributions in combat sports athletes.

The main questions it aims to answer are:

  • Does low-dose caffeinated coffee (1.5 or 3 mg·kg-¹) improve peak power, mean power, and fatigue index during repeated sprint tests?
  • What physiological responses (heart rate, blood lactate, perceived exertion, and energy system contributions) do participants have when consuming caffeinated coffee? Researchers compared caffeinated coffee at two doses (1.5 and 3 mg·kg-¹ body mass) to a placebo (decaffeinated coffee of identical taste and appearance) to see if low

Descripción general del estudio

Descripción detallada

This investigation examined whether acute ingestion of low-dose caffeine delivered through commercially available regular coffee would alter repeated sprint capacity and metabolic energy system dynamics in athletes who compete in combat disciplines. A within-subject, double-blind, placebo-controlled crossover framework was adopted to ensure methodological rigor and minimize order and expectation biases. Eligible participants were physically active male combat sports competitors (n = 15; aged 18-25 years) with a documented competitive history spanning at least five years at the regional and national levels. Volunteers were excluded if they reported recent use of performance-modifying agents, stimulant or psychotropic medications, tobacco products, or any diagnosed condition affecting cardiovascular, metabolic, or musculoskeletal function. To standardize caffeine baseline, all participants were instructed to abstain from caffeinated products for a minimum of two weeks prior to the study onset and throughout the entire data collection period.

Each participant attended the laboratory on four separate occasions. The initial visit served as a familiarization session and included anthropometric assessment. The subsequent three sessions were assigned in a randomized, counterbalanced order, with a minimum 48-hour recovery interval separating each visit. During these sessions, participants received one of three coded supplementation conditions - placebo (decaffeinated coffee), low-dose caffeine (1.5 mg·kg-¹ body mass), or moderate-low-dose caffeine (3 mg·kg-¹ body mass) - each dissolved in 250 mL of hot water and consumed over a 10-minute period. The caffeine content of both the caffeinated and decaffeinated coffee products (Nescafe Gold) was verified by an accredited food analysis laboratory. To maintain identical volume, appearance, and taste across all conditions, decaffeinated and caffeinated coffees were blended in varying proportions for each dose level. Supplementation was administered 60 minutes before the commencement of exercise testing. Performance testing comprised a standardized cycling-based repeated sprint protocol: six 10-second maximal effort sprints, each separated by a 30-second passive recovery period, performed on a mechanically braked cycle ergometer (Monark 894E) with resistance set at 10% of individual body mass. A structured warm-up preceded each testing bout. Primary performance variables derived from sprint testing included peak power output, mean power output, and fatigue index. Perceptual and physiological responses were documented via the Borg rating of perceived exertion scale, peak heart rate, and capillary blood lactate concentration measured at rest and immediately following the final sprint. Breath-by-breath oxygen uptake data were collected continuously using a portable metabolic system (COSMED K5) to facilitate estimation of energy system contributions. The relative and absolute contributions of the phosphocreatine (ATP-PCr), glycolytic, and oxidative metabolic pathways were quantified using established indirect methods. Excess post-exercise oxygen consumption (EPOC) kinetics were modeled with mono-exponential curve fitting to isolate the fast EPOC component, which served as a proxy for PCr resynthesis. Glycolytic contribution was estimated from the net change in blood lactate concentration, applying an established oxygen-equivalent conversion factor. Oxidative metabolism was derived from the net elevation in VO₂ above resting values during exercise. Total energy expenditure was computed as the cumulative sum of all three pathway contributions. To control for dietary and diurnal confounders, participants replicated identical pre-test meal patterns documented during the first testing session, and all laboratory visits were conducted between 08:00 and 11:00 h. Dietary adherence was verified through structured diet logs reviewed by the research team. Data were analyzed using one-way repeated-measures ANOVA with Bonferroni-adjusted pairwise comparisons, and partial eta squared (η²p) was reported as the measure of effect magnitude. The study received full ethical clearance from the Trabzon Eurasia University Ethics Committee and was conducted in accordance with the principles outlined in the Declaration of Helsinki. Informed consent form obtained from all the participants.

Tipo de estudio

Intervencionista

Inscripción (Actual)

15

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Akçaabat
      • Trabzon, Akçaabat, Turquía (Türkiye), 61300
        • Trabzon University Faculty of Sport Sciences

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Male combat sports athletes aged 18 to 25 years
  • Minimum of five years of continuous structured training
  • Competitive experience at both regional (state) and national levels
  • Willingness to abstain from all caffeinated products for two weeks prior to and throughout the study period
  • Ability to follow a standardized dietary protocol prescribed by an Olympic Preparation Center dietitian
  • Provision of written informed consent

Exclusion Criteria:

  • Age below 18 years
  • Self-reported use of anabolic agents, hormonal modulators, or performance-influencing dietary supplements within the three months preceding enrollment
  • Current use of narcotic, psychotropic, stimulant medications, or tobacco products during the assessment period
  • Presence of any diagnosed medical condition (including cardiovascular, metabolic, neurological, respiratory, or musculoskeletal disorders) that may compromise safe participation
  • Withdrawal from the study at the participant's own request

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Placebo
Participants ingested decaffeinated coffee (Nescafe Gold, decaffeinated) at a dose equivalent to 3 mg·kg-¹ of body mass, dissolved in 250 mL of hot water and consumed over 10 minutes, administered 60 minutes before the exercise test.
A standardized cycling-based repeated sprint protocol consisting of six 10-second maximal-effort sprints, each separated by a 30-second passive rest interval, performed on a mechanically braked cycle ergometer (Monark 894E, Vansbro, Sweden). Resistance was calibrated at 10% of the participant's individual body mass. The inertial momentum of the flywheel was excluded from power output calculations following the approach described by Bogdanis et al. (2008). Each session was preceded by a structured warm-up consisting of five 30-second bouts at 100 W, followed by a 5-minute seated rest before test commencement. Each participant initiated the protocol with their dominant leg to ensure procedural consistency across all sessions.
Continuous breath-by-breath oxygen uptake (VO₂) data were collected throughout each testing session using the COSMED K5 portable metabolic system (Rome, Italy). Data were used to estimate the relative and absolute contributions of the three metabolic energy pathways. The fast component of excess post-exercise oxygen consumption (EPOC) was extracted and modeled using a mono-exponential function (OriginPro 8.0, OriginLab Corp.) to estimate phosphocreatine (PCr) resynthesis during recovery intervals and following the final sprint. Oxidative metabolism contribution was derived by subtracting resting VO₂ from exercise VO₂. Total energy demand was expressed in both liters of O₂ and kilojoules (caloric equivalent: 20.92 kJ·L-¹ O₂).
Capillary blood samples were obtained at two time points per session: (1) resting lactate (LA_rest) - collected following a 20-minute passive rest period immediately before the sprint test, in accordance with published lactate clearance protocols; and (2) maximal post-exercise lactate (LA_max) - collected immediately upon completion of the final sprint repetition. Delta lactate (ΔLA) was calculated as the arithmetic difference between LA_max and LA_rest and expressed in mmol·L-¹. Delta lactate values were additionally used to estimate the glycolytic energy system contribution, applying a conversion factor of 3 mL O₂·kg-¹ body mass per 1 mmol·L-¹ increase in blood lactate concentration (Di Prampero & Ferretti, 1999).
Continuous heart rate was recorded throughout each testing session via chest type radiotelemetry sensor integrated with COSMED K5. Peak heart rate (HR_peak, bpm) was defined as the highest value observed across the entire repeated sprint protocol and reported as a secondary physiological outcome.
Experimental: Low-Dose Caffeine - 1.5 mg·kg-¹
A blended preparation of caffeinated and decaffeinated (for the similar taste of intensity with 3 mg/kg intervention) Nescafe Gold coffee dissolved in 250 ml hot water was administered at a total dose corresponding to 1.5 mg·kg-¹ body mass of caffeine. Volume was equalized to the placebo condition through addition of decaffeinated coffee.
A standardized cycling-based repeated sprint protocol consisting of six 10-second maximal-effort sprints, each separated by a 30-second passive rest interval, performed on a mechanically braked cycle ergometer (Monark 894E, Vansbro, Sweden). Resistance was calibrated at 10% of the participant's individual body mass. The inertial momentum of the flywheel was excluded from power output calculations following the approach described by Bogdanis et al. (2008). Each session was preceded by a structured warm-up consisting of five 30-second bouts at 100 W, followed by a 5-minute seated rest before test commencement. Each participant initiated the protocol with their dominant leg to ensure procedural consistency across all sessions.
Continuous breath-by-breath oxygen uptake (VO₂) data were collected throughout each testing session using the COSMED K5 portable metabolic system (Rome, Italy). Data were used to estimate the relative and absolute contributions of the three metabolic energy pathways. The fast component of excess post-exercise oxygen consumption (EPOC) was extracted and modeled using a mono-exponential function (OriginPro 8.0, OriginLab Corp.) to estimate phosphocreatine (PCr) resynthesis during recovery intervals and following the final sprint. Oxidative metabolism contribution was derived by subtracting resting VO₂ from exercise VO₂. Total energy demand was expressed in both liters of O₂ and kilojoules (caloric equivalent: 20.92 kJ·L-¹ O₂).
Capillary blood samples were obtained at two time points per session: (1) resting lactate (LA_rest) - collected following a 20-minute passive rest period immediately before the sprint test, in accordance with published lactate clearance protocols; and (2) maximal post-exercise lactate (LA_max) - collected immediately upon completion of the final sprint repetition. Delta lactate (ΔLA) was calculated as the arithmetic difference between LA_max and LA_rest and expressed in mmol·L-¹. Delta lactate values were additionally used to estimate the glycolytic energy system contribution, applying a conversion factor of 3 mL O₂·kg-¹ body mass per 1 mmol·L-¹ increase in blood lactate concentration (Di Prampero & Ferretti, 1999).
Continuous heart rate was recorded throughout each testing session via chest type radiotelemetry sensor integrated with COSMED K5. Peak heart rate (HR_peak, bpm) was defined as the highest value observed across the entire repeated sprint protocol and reported as a secondary physiological outcome.
Experimental: Low-Dose Caffeine - 3 mg·kg-¹
Regular caffeinated Nescafe Gold coffee dissolved in 250 ml hot water was administered at a dose delivering 3 mg·kg-¹ body mass of caffeine.
A standardized cycling-based repeated sprint protocol consisting of six 10-second maximal-effort sprints, each separated by a 30-second passive rest interval, performed on a mechanically braked cycle ergometer (Monark 894E, Vansbro, Sweden). Resistance was calibrated at 10% of the participant's individual body mass. The inertial momentum of the flywheel was excluded from power output calculations following the approach described by Bogdanis et al. (2008). Each session was preceded by a structured warm-up consisting of five 30-second bouts at 100 W, followed by a 5-minute seated rest before test commencement. Each participant initiated the protocol with their dominant leg to ensure procedural consistency across all sessions.
Continuous breath-by-breath oxygen uptake (VO₂) data were collected throughout each testing session using the COSMED K5 portable metabolic system (Rome, Italy). Data were used to estimate the relative and absolute contributions of the three metabolic energy pathways. The fast component of excess post-exercise oxygen consumption (EPOC) was extracted and modeled using a mono-exponential function (OriginPro 8.0, OriginLab Corp.) to estimate phosphocreatine (PCr) resynthesis during recovery intervals and following the final sprint. Oxidative metabolism contribution was derived by subtracting resting VO₂ from exercise VO₂. Total energy demand was expressed in both liters of O₂ and kilojoules (caloric equivalent: 20.92 kJ·L-¹ O₂).
Capillary blood samples were obtained at two time points per session: (1) resting lactate (LA_rest) - collected following a 20-minute passive rest period immediately before the sprint test, in accordance with published lactate clearance protocols; and (2) maximal post-exercise lactate (LA_max) - collected immediately upon completion of the final sprint repetition. Delta lactate (ΔLA) was calculated as the arithmetic difference between LA_max and LA_rest and expressed in mmol·L-¹. Delta lactate values were additionally used to estimate the glycolytic energy system contribution, applying a conversion factor of 3 mL O₂·kg-¹ body mass per 1 mmol·L-¹ increase in blood lactate concentration (Di Prampero & Ferretti, 1999).
Continuous heart rate was recorded throughout each testing session via chest type radiotelemetry sensor integrated with COSMED K5. Peak heart rate (HR_peak, bpm) was defined as the highest value observed across the entire repeated sprint protocol and reported as a secondary physiological outcome.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Peak Power Output
Periodo de tiempo: On 3 testing days with 48-hour interval
Highest instantaneous power output (Watts) recorded across all six 10-second sprint bouts on the cycle ergometer (Monark 894E), with resistance set at 10% of body mass.
On 3 testing days with 48-hour interval
Mean Power Output
Periodo de tiempo: On 3 testing days with 48-hour interval
Average power output (Watts) calculated across all six sprint efforts, reflecting the athlete's overall capacity to sustain high-intensity output across the full protocol.
On 3 testing days with 48-hour interval
Fatigue Index
Periodo de tiempo: On 3 testing days with 48-hour interval
Quantified as: FI = 100 × (1 - total peak power / ideal peak power), where ideal peak power is the product of the highest single-sprint peak power and the total number of repetitions. Expressed as a percentage (%).
On 3 testing days with 48-hour interval

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Total Energy Expenditure
Periodo de tiempo: On 3 testing days with 48-hour interval
Computed as the cumulative sum of ATP-PCr, glycolytic, and oxidative pathway contributions, expressed in kilojoules (kJ), using a caloric equivalent of 20.92 kJ per liter of O₂ consumed.
On 3 testing days with 48-hour interval
Energy System - Oxidative Contribution
Periodo de tiempo: On 3 testing days with 48-hour interval
Estimated absolute contributions (kJ) of each metabolic pathway. Oxidative contribution calculated as net VO₂ elevation above resting baseline. Breath-by-breath VO₂ data collected continuously via COSMED K5 portable metabolic system.
On 3 testing days with 48-hour interval
Energy System - ATP Contribution
Periodo de tiempo: On 3 testing days with 48-hour interval
ATP-PCr contribution derived from the fast component of EPOC kinetics modeled via mono-exponential curve fitting (OriginPro 8.0).
On 3 testing days with 48-hour interval
Energy System - Glycolytic Contribution
Periodo de tiempo: On 3 testing days with 48-hour interval
Glycolytic contribution estimated from net blood lactate rise (3 mL O₂·kg-¹ per 1 mmol·L-¹ increase).
On 3 testing days with 48-hour interval
Peak Heart Rate
Periodo de tiempo: On 3 testing days with 48-hour interval
Highest recorded heart rate (bpm) during the repeated sprint test.
On 3 testing days with 48-hour interval
Delta Blood Lactate Concentration
Periodo de tiempo: On 3 testing days with 48-hour interval
Difference between resting capillary blood lactate (measured after 20-minute passive rest prior to testing) and maximum post-exercise lactate (measured immediately following the final sprint). Expressed in mmol·L-¹.
On 3 testing days with 48-hour interval
Rating of Perceived Exertion
Periodo de tiempo: On 3 testing days with 48-hour interval
Subjective effort rating collected using the Borg scale (6-20) following the completion of the repeated sprint protocol.
On 3 testing days with 48-hour interval

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de abril de 2025

Finalización primaria (Actual)

30 de mayo de 2025

Finalización del estudio (Actual)

30 de mayo de 2025

Fechas de registro del estudio

Enviado por primera vez

12 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de mayo de 2026

Publicado por primera vez (Actual)

19 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • E-69268593-050.04-25025

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

All the data collected in this study anonymized and only will be used in the scope of academic paper publication.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir